dispensable polypeptide and a synthetic molecule of interest can be prepared *in vitro* and bound to surface lattice proteins. In another embodiment, a positive selection vector forces integration of a gene that encodes a dispensable polypeptide and a polypeptide of interest into the genome of a phage from which the wild type dispensable polypeptide is deleted. For example, a modified *soc* gene can be integrated into a *soc*-deleted T4 genome, leading to *in vivo* binding of the display molecule on progeny virions. More than one type of dispensable polypeptide can be used as part of the chimera for displaying one or more molecules of interest. For example, the surface lattice proteins of a phage may be bound to a chimera that contains SOC and a chimera that contains HOC.

The display system has been successfully demonstrated for three molecules of interest that vary in their length and character: (1) a tetrapeptide; (2) the 43 amino acid residue V3 loop domain of gp120, the human immunodeficiency virus type-1 (HIV–1) envelope glycoprotein; and (3) poliovirus VP1 capsid protein (312 residues).

Ultrasound-Hall Effect Imaging System and Method

H Wen (NHLBI)

DHHS Reference No. E–067–96/0; PCT/US97/11272 filed 03 Jul 97 Licensing Contact: John Fahner-Vihtelic, 301/496–7735 ext. 270

The present application provides for a new ultrasound-based imaging modality that is based on the interaction among a static magnetic field and conductive moieties in the imaged sample under electrical excitation. The application also provides a new ultrasound-based imaging modality that provides a contrast mechanism which reflects the conductivity distribution of the medium being imaged. The disclosed methods and system are advantageous over other ultrasonic imaging systems in the following aspects: it provides a method which is not limited to contrast based solely on acoustic properties; it dispenses with acoustic beam excitation, and therefore is suitable for fast 2D and 3D image formation with wide angle signal reception. A working prototype system is in testing and the present invention is suitable for development into commercial computed imaging products for biomedical imaging and industrial non-destructive testing.

Multideterminant Peptide Antigens That Stimulate Helper T Lymphocyte Response to HIV in a Range of Human Subjects

JA Berzofsky, JD Ahlers, PL Nara, M Shirai, CD Pendleton (NCI) Serial No. 08/060,988 filed 14 May 93; PCT/US94/05142 filed 13 May 94

Licensing Contact: Robert Benson, 301/496–7056 ext. 267

A vaccine for the prevention and/or treatment of HIV infection would ideally elicit a response in a broad range of the population. It would also have the capability of inducing high titered neutralizing antibodies, cytotoxic T lymphocytes, and helper T cells specific for HIV–1 gp 160 envelope protein. A vaccine based on synthetic or recombinant peptides has been developed which elicits these responses while avoiding the potential safety risks of live or killed viruses. Unlike previously developed vaccines this invention avoids those regions of gp 160 which may contribute to acceleration of infection or the development of immune deficiency. This invention provides peptides up to 44 amino acid residues long that stimulate helper T-cell response to HIV in a range of human subjects. Six multideterminant regions have been identified in which overlapping peptides are recognized by mice of either three or all four MHC types. Four of the six regions have sequences relatively conserved among HIV–I isolates. These multideterminant cluster peptides are recognized by T cells from humans of multiple HLA types, and have been found in a phase I clinical trial to elicit neutralizing antibodies, cytotoxic T cells, and helper T cells in at least some of the human subjects.

Mucosal Cytotoxic T Lymphocyte Responses

J. Berzofsky, I Belyakov, M Derby, B Kelsall, W Strober (NCI)

DHHS Reference No. E–268–97/1 (incorporating USSN 60/058,523) filed 17 Feb 98 (priority to 11 July 97)

Licensing Contact: Robert Benson, 301–496–7056 ext. 267

This invention is the discovery that intrarectal (IR) administration of a peptide antigen can induce an antigen-specific, protective CTL response in the mucosal and systemic immune system. The CTL response is much greater than occurs with intranasal administration. The CTL response is enhanced by co-administration of a mucosal adjuvant such as cholera toxin, and is further enhanced by IR administration of interleukin 12 (IL–12). IR administration of an HIV–1 peptide vaccine protected mice against an IR challenge with a recombinant vaccinia virus expressing HIV gp160. This invention provides an approach to the use of peptide vaccines that protect against mucosal infection, especially for HIV. The invention is further described in Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1709–1714, 1998.

Dated: March 31, 1998.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 98–9177 Filed 4–7–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: April 8, 1998.

Time: 4:00 p.m.

Place: NIH, Rockledge 2, Room 5190, Telephone Conference.

Contact Person: Dr. Herman Teitelbaum, Scientific Review Administrator, 6701 Rockledge Drive, Room 5190, Bethesda, Maryland 20892, (301) 435–1254.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 14, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4194, Telephone Conference.

Contact Person: Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4194, Bethesda, Maryland 20892, (301) 435–1146.

Name of SEP: Biological and Physiological Sciences.

Date: April 14, 1998.

Time: 10:00 a.m.

Place: NIH, Rockledge 2, Room 5202, Telephone Conference.

Contact Person: Dr. Anita Sostek Miller, Scientific Review Administrator, 6701 Rockledge Drive, Room 5202, Bethesda, Maryland 20892, (301) 435–1260.

Name of SEP: Biological and Physiological Sciences.

Date: April 14, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4142, Telephone Conference.

Contact Person: Dr. Edmund Copeland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4142, Bethesda, Maryland 20892, (301) 435–1715.

Name of SEP: Biological and Physiological Sciences.
Date: April 15, 1998.
Time: 2:00 p.m.
Place: NIH, Rockledge 2, Room 4142, Telephone Conference.
Contact Person: Dr. Edmund Copeland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4142, Bethesda, Maryland 20892, (301) 435–1715.

Name of SEP: Biological and Physiological Sciences.
Date: April 17, 1998.
Time: 12:00 p.m.
Place: NIH, Rockledge 2, Room 4142, Telephone Conference.
Contact Person: Dr. Edmund Copeland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4142, Bethesda, Maryland 20892, (301) 435–1715.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Biological and Physiological Sciences.
Date: April 20, 1998.
Time: 1:00 p.m.
Place: NIH, Rockledge 2, Room 4146, Telephone Conference.
Contact Person: Dr. Martin Padarathsingh, Scientific Review Administrator, 6701 Rockledge Drive, Room 4146, Bethesda, Maryland 20892, (301) 435–1717.

Name of SEP: Biological and Physiological Sciences.
Date: April 21, 1998.
Time: 2:00 p.m.
Place: NIH, Rockledge 2, Room 4150, Telephone Conference.
Contact Person: Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, Maryland 20892, (301) 435–1719.

Name of SEP: Biological and Physiological Sciences.
Date: April 22, 1998.
Time: 2:00 p.m.
Place: NIH, Rockledge 2, Room 5170, Telephone Conference.
Contact Person: Dr. Luigi Giacometti, Scientific Review Administrator, 6701 Rockledge Drive, Room 5170, Bethesda, Maryland 20892, (301) 435–1246.

Name of SEP: Biological and Physiological Sciences.
Date: April 23, 1998.
Time: 10:30 a.m.
Place: NIH, Rockledge 2, Room 4182, Telephone Conference.
Contact Person: Dr. William Branche, Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, Maryland 20892, (301) 435–1148.

Name of SEP: Biological and Physiological Sciences.
Date: April 29, 1998.
Time: 11:00 a.m.
Place: NIH, Rockledge 2, Room 4150, Telephone Conference.
Contact Person: Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, Maryland 20892, (301) 435–1719.

Name of SEP: Biological and Physiological Sciences.
Date: May 1, 1998.
Time: 2:00 p.m.
Place: NIH, Rockledge 2, Room 6178, Telephone Conference.
Contact Person: Dr. Nancy Pearson, Scientific Review Administrator, 6701 Rockledge Drive, Room 6178, Bethesda, Maryland 20892, (301) 435–1047.

Name of SEP: Clinical Sciences.
Date: June 2, 1998.
Time: 8:00 a.m.
Place: Holiday Inn, Silver Spring, MD.
Contact Person: Dr. Gertrude McFarland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4110, Bethesda, Maryland 20892, (301) 435–1784.

Name of SEP: Behavioral and Neurosciences.
Date: June 2–4, 1998.
Time: 8:30 a.m.
Place: Holiday Inn, Chevy Chase, MD.
Contact Person: Dr. Gamil Debbas, Scientific Review Administrator, 6701 Rockledge Drive, Room 5170, Bethesda, Maryland 20892, (301) 435–1018.

Name of SEP: Behavioral and Neurosciences.
Date: June 8–9, 1998.
Time: 8:30 a.m.
Place: One Washington Circle, Washington, DC.
Contact Person: Dr. Joseph Kimm, Scientific Review Administrator, 6701 Rockledge Drive, Room 5178, Bethesda, Maryland 20892, (301) 435–1249.

Name of SEP: Behavioral and Neurosciences.
Date: June 17–19, 1998.
Time: 8:30 a.m.
Place: Ramada Inn, Rockville, MD.
Contact Person: Dr. Laurence Stanford, Scientific Review Administrator, 6701 Rockledge Drive, Room 5176, Bethesda, Maryland 20892, (301) 435–1255.

Name of SEP: Clinical Sciences.
Date: June 24, 1998.
Time: 8:00 a.m.
Place: Holiday Inn, Silver Spring, MD.
Contact Person: Dr. Gertrude McFarland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4110, Bethesda, Maryland 20892, (301) 435–1784.

Name of SEP: Behavioral and Neurosciences.
Date: June 24–25, 1998.
Time: 8:30 a.m.
Place: Ramada Inn, Rockville, MD.
Contact Person: Dr. Laurence Stanford, Scientific Review Administrator, 6701 Rockledge Drive, Room 5176, Bethesda, Maryland 20892, (301) 435–1255.

Name of SEP: Behavioral and Neurosciences.
Date: June 24–26, 1998.
Time: 8:30 a.m.
Place: Holiday Inn-Capitol, Washington, DC.
Contact Person: Dr. Samuel Rawlings, Scientific Review Administrator, 5160 Rockledge Drive, Room 5160, Bethesda, Maryland 20892, (301) 435–1243.

Name of SEP: Behavioral and Neurosciences.
Date: June 25–26, 1998.
Time: 8:30 a.m.
Place: Holiday Inn, Chevy Chase, MD.
Contact Person: Dr. Richard Marcus, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435–1245.

Name of SEP: Behavioral and Neurosciences.
Date: June 25–27, 1998.
Time: 8:30 a.m.
Place: One Washington Circle, Washington, DC.
Contact Person: Dr. Bernard Driscoll, Scientific Review Administrator, 6701 Rockledge Drive, Room 5158, Bethesda, Maryland 20892, (301) 435–1242.

Name of SEP: Behavioral and Neurosciences.
Date: June 29-July 1, 1998.
Time: 8:30 a.m.
Place: Clarion Hampshire Hotel, Washington, DC.
Contact Person: Dr. Jay Cinque, Scientific Review Administrator, 6701 Rockledge Drive, Room 5186, Bethesda, Maryland 20892, (301) 435–1252.

Name of SEP: Behavioral and Neurosciences.
Date: June 30-July 1, 1998.
Time: 8:30 a.m.
Place: Holiday Inn, Chevy Chase, MD.
Contact Person: Dr. Richard Marcus, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435–1245.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 1, 1998.

LaVerne Y. Springfield,

Committee Management Officer, NIH.

[FR Doc. 98–9225 Filed 4–7–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting: